29.19

2.37% -0.71

Zymeworks Inc. (ZYME)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$29.90

Offen:

$29.81

24-Stunden-Volumen:

452.93K

Relative Volume:

0.76

Marktkapitalisierung:

$2.09B

Einnahmen:

$81.26M

Nettoeinkommen (Verlust:

$-102.66M

KGV:

-21.34

EPS:

-1.3678

Netto-Cashflow:

$-77.62M

1W Leistung:

+3.25%

1M Leistung:

+28.08%

6M Leistung:

+15.70%

1J Leistung:

+107.32%

1-Tages-Spanne:

$29.09

$29.99

1-Wochen-Bereich:

$27.81

$31.34

52-Wochen-Spanne:

$14.06

$31.34

Zymeworks Inc. Stock (ZYME) Company Profile

Firmenname

Zymeworks Inc.

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

604-678-1388

Adresse

1385 West 8th Avenue, Suite 540, Vancouver, BC

Mitarbeiter

170

Twitter

@ZymeworksInc

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ZYME Zymeworks Inc.	29.19	1.90B	81.26M	-102.66M	-77.62M	-1.3678
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-12	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-12-03	Eingeleitet	Citizens JMP	Mkt Outperform
2025-10-24	Fortgesetzt	Wells Fargo	Equal Weight
2025-10-14	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-10-10	Eingeleitet	B. Riley Securities	Buy
2025-05-20	Eingeleitet	TD Cowen	Buy
2024-12-16	Hochstufung	JP Morgan	Neutral → Overweight
2024-11-07	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-11-01	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-03-21	Fortgesetzt	Wells Fargo	Overweight
2023-01-04	Bestätigt	H.C. Wainwright	Neutral
2022-12-20	Hochstufung	Jefferies	Hold → Buy
2022-11-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-10-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-10-04	Fortgesetzt	Wells Fargo	Overweight
2022-05-05	Hochstufung	Guggenheim	Neutral → Buy
2022-03-15	Eingeleitet	Evercore ISI	Outperform
2021-12-10	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-11-17	Fortgesetzt	Guggenheim	Neutral
2021-10-07	Eingeleitet	Jefferies	Hold
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-02-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-02-08	Fortgesetzt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	Citigroup	Buy → Neutral
2020-09-29	Fortgesetzt	JP Morgan	Neutral
2020-08-06	Eingeleitet	SVB Leerink	Outperform
2020-01-10	Eingeleitet	Wolfe Research	Outperform
2019-12-09	Eingeleitet	JP Morgan	Neutral
2019-11-25	Eingeleitet	H.C. Wainwright	Buy
2019-11-20	Eingeleitet	Guggenheim	Buy
2019-09-30	Hochstufung	Raymond James	Outperform → Strong Buy
2019-08-30	Eingeleitet	Stifel	Buy
2019-07-18	Eingeleitet	Deutsche Bank	Buy
2018-05-11	Hochstufung	Barclays	Underweight → Equal Weight
2018-03-19	Eingeleitet	Raymond James	Outperform

Alle ansehen

Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten

Aug 21, 2026

Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan

Aug 21, 2026

Aug 18, 2026

Enterprise value to revenue forward of Zymeworks Inc. – SWB:ZA8 - TradingView

Aug 18, 2026

Zymeworks (ZYME) Session Brief: Climbs 2.69% to $25.99 in the Latest Session; Reference Levels: $24.69 and $27.29 Define the Nearby Reference Levels at the ClosePCR Spike - vinanet.vn

Aug 18, 2026

Aug 17, 2026

How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story - simplywall.st

Aug 17, 2026

Aug 15, 2026

ZYME Q2 2026 Earnings: Wider-than-Expected Loss of -$0.62 per Share Reflects Clinical-Stage InvestmentProduct Revenue Analysis - vinanet.vn

Aug 15, 2026

Aug 12, 2026